Outcome | Men | Women | ||||
---|---|---|---|---|---|---|
2015 | 2020 | Difference (95% CI)* | 2015 | 2020 | Difference (95% CI)* | |
HbA1c ≤ 7.0 | ||||||
All | 57.4 | 58.9 | 1.5 (0.5 to 2.5)† | 61.7 | 63.8 | 2.1 (1.1 to 3.1)† |
< 40 yr | 45.5 | 51.5 | 6.0 (0.5 to 11.4)† | 57.3 | 64.7 | 7.4 (2.7 to 12.1)† |
40–64 yr | 53.8 | 56.5 | 2.7 (1.3 to 4.1)† | 57.9 | 62.0 | 4.0 (2.6 to 5.5)† |
65–79 yr | 62.4 | 61.7 | −0.8 (−2.2 to 0.6) | 66.4 | 65.5 | −0.8 (−2.3 to 0.6) |
Blood pressure ≤ 130/80 mm Hg | ||||||
All | 47.6 | 43.1 | −4.5 (−5.5 to −3.5)† | 50.2 | 45.6 | −4.5 (−5.6 to −3.5)† |
< 40 yr | 50.4 | 40.6 | −9.8 (−15.2 to −4.3)† | 61.4 | 49.2 | −12.1 (−16.8 to −7.4)† |
40–64 yr | 45.0 | 40.1 | −4.8 (−6.2 to −3.5)† | 51.0 | 45.8 | −5.2 (−6.6 to −3.7)† |
65–79 yr | 50.3 | 46.0 | −4.3 (−5.7 to −2.8)† | 48.1 | 45.0 | −3.1 (−4.6 to −1.5)† |
LDL-C ≤ 2.00 mmol/L | ||||||
All | 54.8 | 59.4 | 4.6 (3.6 to 5.6)† | 43.0 | 45.8 | 2.8 (1.7 to 3.8)† |
< 40 yr | 31.4 | 33.0 | 1.5 (−3.6 to 6.7) | 27.2 | 26.8 | −0.4 (−4.6 to 3.8) |
40–64 yr | 48.3 | 51.4 | 3.1 (1.7 to 4.5)† | 36.9 | 38.7 | 1.7 (0.3 to 3.2)† |
65–79 yr | 63.9 | 68.8 | 4.8 (3.5 to 6.2)† | 51.5 | 55.2 | 3.7 (2.1 to 5.2)† |
All 3 clinical targets | ||||||
All | 15.9 | 16.5 | 0.6 (−0.1 to 1.3) | 13.0 | 13.3 | 0.3 (−0.4 to 1.0) |
< 40 yr | 6.3 | 7.8 | 1.5 (−1.3 to 4.3) | 10.3 | 9.2 | −1.2 (−4.0 to 1.7) |
40–64 yr | 12.4 | 12.8 | 0.4 (−0.6 to 1.3) | 10.4 | 10.9 | 0.6 (−0.3 to 1.5) |
65–79 yr | 20.5 | 20.6 | 0.0 (−1.1 to 1.2) | 16.4 | 16.2 | −0.1 (−1.2 to 1.0) |
Statin use | ||||||
All | 53.9 | 54.0 | 0.1 (−0.9 to 1.1) | 47.4 | 45.3 | −2.2 (−3.2 to −1.1)† |
< 40 yr | 25.1 | 18.5 | −6.6 (−12.2 to −1.0)† | 14.3 | 8.6 | −5.6 (−9.3 to −2.0)† |
40–64 yr | 51.3 | 50.1 | −1.1 (−2.5 to 0.3) | 42.8 | 39.3 | −3.6 (−5.0 to −2.1)† |
65–79 yr | 58.3 | 59.1 | 0.8 (−0.6 to 2.2) | 55.2 | 54.4 | −0.8 (−2.3 to 0.7) |
ACE inhibitor or ARB use | ||||||
All | 53.2 | 51.9 | −1.2 (−2.2 to −0.2)† | 48.8 | 46.5 | −2.3 (−3.4 to −1.3)† |
< 40 yr | 32.4 | 25.6 | −6.9 (−12.7 to −1.1)† | 20.1 | 13.8 | −6.3 (−10.4 to −2.2)† |
40–64 yr | 50.7 | 48.7 | −2.0 (−3.4 to −0.5)† | 44.5 | 41.2 | −3.4 (−4.9 to −1.9)† |
65–79 yr | 57.0 | 56.1 | −0.9 (−2.3 to 0.6) | 55.6 | 54.4 | −1.3 (−2.8 to 0.3) |
Note: ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CI = confidence interval, HbA1c = glycated hemoglobin, LDL-C = low-density lipoprotein cholesterol.
↵* Difference shown is an absolute difference in proportions, 2020 minus 2015.
↵† Significant difference (p < 0.05); p values obtained from simple Z-tests of the difference.